Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Drug developers reboot anti-NGF pain programmes

Nature Reviews Drug Discovery volume 14, pages 297–298 (2015)Cite this article

Subjects

Pfizer, Eli Lilly, Janssen and Regeneron are advancing a promising class of analgesic drugs, hoping to put concerns around autonomic dysfunction and joint destruction behind them.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Drug developers reboot anti-NGF pain programmes. Nat Rev Drug Discov 14, 297–298 (2015). https://doi.org/10.1038/nrd4612

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4612

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research